ARS Pharmaceuticals, Inc. (SPRY) is a San Diego-based biopharmaceutical company commercializing neffy, the only needle-free epinephrine nasal spray approved by the U.S. Food and Drug Administration for emergency treatment of severe allergic reactions, including anaphylaxis. The company is also developing ARS-2 as a potential on-demand treatment for breakthrough flares of chronic spontaneous urticaria.
Shares traded at $3.39 at mid-morning on Nov. 19, down 8.13%, or $0.30, from the prior completed session's close of $3.69. The direction is unambiguously lower. No verified company-specific catalyst — earnings release, regulatory disclosure, financing, partnership or analyst rating change — was identified for the session, leaving the move to be explained by positioning, liquidity and the stock's own recent trading pattern.
No verified news or fundamental catalyst found in company disclosures, filings or major market coverage accounts for the session's decline. The most recent material corporate event remains the third-quarter report on Nov. 5, which showed revenue of $37.7 million, up 16% year over year, but below the roughly $42 million consensus, with a net loss of $35.6 million, or $0.36 per share. Several price targets were trimmed the following day, but that news is two weeks old and coincided with a rebound, not a selloff.
The more likely explanation is technical and flow-driven. The stock bottomed at $2.44 on Nov. 6, then ripped higher by 12.90%, 13.33% and 10.64% in three consecutive sessions, stalling at $4.13 on Nov. 11. That is a roughly 69% move off the low in three sessions, and the shares have since struggled to reclaim $4.00 — consistent with profit-taking and exhaustion in a heavily shorted micro-cap. With about 19.0 million shares sold short, equal to roughly 39% of the roughly 49 million-share float, and a short ratio near 11.5 days, the order book is thin enough that modest flows produce outsized percentage moves. The stock has also posted seven sessions with double-digit absolute moves over the past three months, a pattern consistent with speculative trading rather than a single identifiable event.
Trading liquidity is modest: three-month average volume is around 1.8 million shares, with the 20-day average nearer 2.4 million, a scale at which a few hundred thousand shares of net selling can move the price several percent. The decline also leaves the stock well below its 50-day moving average near $3.97 and far beneath its 200-day average around $6.94, keeping the medium-term trend definitively negative even after the early-November bounce.
Positioning is the other visible pressure point. Short interest of roughly 19 million shares, near 19% of shares outstanding, means rallies have been met with fresh shorting and long-side profit-taking rather than sustained accumulation. The 52-week range of $2.44 to $13.15 illustrates the scale of the repricing: the shares are down about 50% over twelve months and roughly 68% year to date, and remain less than 40% above their November low.
Nothing in the available record points to a sector-wide or index-level event behind the move; the decline appears concentrated in the name itself, which is typical of a low-float, heavily traded biotech trading on sentiment rather than news.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move.
This event scores 14 out of 100. Verified news was effectively absent: no new filing, guidance revision, clinical readout or rating action surfaced during the session, and the most recent material development — the third-quarter revenue miss — dates to Nov. 5 and is not large enough relative to the company's roughly $340 million market value to explain a fresh 8% slide. On the price side, the 8.13% decline is about 2.2 times the stock's typical absolute daily move of roughly 3.75%, and moves of similar or greater size have occurred five times in the last 60 sessions. Unusual, but not rare for this name — which is why the score sits in the low teens despite the sharp headline number.
The next hard catalyst is the fourth-quarter report, expected in early March, when management has said it will issue its first full-year 2027 financial outlook alongside results. Investors will focus on neffy's U.S. net product revenue trajectory, overall market share above the 5% reported for the third quarter, field-targeted account share near 9%, and whether the roughly 42% reduction in selling, general and administrative spending holds through 2027.
Payer access is the central uncertainty. Management has flagged that more than 80% of commercial lives are covered, though prior authorization requirements remain a friction point, and expanded coverage from a large pharmacy benefit manager has been deferred to January 2027. Progress — or further delay — on Medicaid and commercial formulary gaps would move expectations materially.
On the pipeline, interim Phase 2b data for ARS-2 in chronic spontaneous urticaria is expected in the first quarter of 2027, with full data later in the year to inform Phase 3 design. The balance sheet carries $138.4 million in cash and short-term investments, with management targeting cash-flow breakeven by the end of 2027; any deviation from that path, ongoing securities litigation, or renewed dilution risk would weigh on sentiment. Volatility should be assumed to persist given the short interest and thin float.
Tickeron's Trending AI Robots page curates the platform's strongest-performing automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only those posting the best results right now make this featured list. Bots differ by strategy logic, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions change. For readers navigating volatile names like this one, reviewing the trending roster is a practical way to see which approaches are working today.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Moving Average Convergence Divergence (MACD) for SPRY turned positive on November 11, 2026. Looking at past instances where SPRY's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SPRY's RSI Oscillator exited the oversold zone, 30 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on SPRY as a result. In 80 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in 234 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for SPRY entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.175) is normal, around the industry mean (3.592). P/E Ratio (-1.280) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology